BACKGROUND Human reproduction depends on an intact hypothalamic–pituitary–gonadal
(HPG) axis. Hypothalamic gonadotrophin-releasing hormone (GnRH) has been recognized …

The use of peptide analogs for the therapy of various cancers is reviewed. Inhibition of the
pituitary–gonadal axis forms the basis for oncological applications of luteinizing hormone …

In several human malignant tumors of the urogenital tract, including cancers of the
endometrium, ovary, urinary bladder, and prostate, it has been possible to identify …

The crucial role of pituitary GnRH receptors (GnRH-R) in the control of reproductive
functions is well established. These receptors are the target of GnRH agonists (through …

The development of the luteinizing hormone-releasing hormone (LH-RH) agonists and
antagonists and the principles of their clinical use were reviewed. In the 28 years that have …

The “ovarian cycle” is an exquisite and dynamic endocrine system that includes ovarian
events, hypothalamic–pituitary interactions, uterine endometrial and myometrial changes …

The expression of GnRH and its receptor as a part of an autocrine regulatory system of cell
proliferation has been demonstrated in a number of human malignant tumors, including …

Gonadotropin‐releasing hormone (GnRH) has historically been known as a pituitary
hormone; however, in the past few years, interest has been raised in locally produced …

Two classes of luteinising hormone-releasing hormone (LHRH) analogues have been
developed so far to be used for oncological therapies: LHRH agonists and antagonists …

The ability of gonadotropins to act on and regulate normal ovarian surface epithelial (OSE)
cells and ovarian cancer cells was investigated. Bovine OSE was used as a model to study …